Similarly, type I angiotensin II receptors were reported to regulate CCL2 in prostate cancer and pancreatic cancer cells, suggesting that losartan, and potentially other type I angiotensin II receptor blockers, could be repurposed for use in cancer immunotherapy [106,107]. Here, CCL2 is linked to prostate cancer.